ArticleMolecular therapy. Advances2026
Engineered T7 RNA polymerase to improve mRNA capping efficiency and reduce dsRNA generation during
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As mRNA emerges as a versatile tool for treating a range of diseases, efficient and scalable production remains an ongoing challenge. Inefficient co-transcriptional incorporation of cap analogs and generation of double-stranded RNA impurities are two of the major challenges that can result in increased manufacturing costs and time, as well as increased immunogenicity and reduced therapeutic potency. In an effort to overcome these challenges, we engineered T7 RNA polymerase variants to enhance capping efficiency and reduce dsRNA generation. In this work, we screened 59 T7 RNA polymerase variants and identified multiple variants, most notably R632N and Q649L, that achieved higher capping efficiency and up to 90% reduction in dsRNA impurity without compromising mRNA integrity. mRNA generated by these engineered T7 RNA polymerase variants showed enhanced translation and reduced immunogenicity in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.